FACTORS ASSOCIATED WITH HYPERTENSION PREVALENCE AND CONTROL AMONG LEBANESE TYPE 2 DIABETIC PATIENTS

LAMA SOUBRA*, HANAN NUREDDIN, AMAL GALAL OMAR, MOUNZER SALEH
Pharmacy Practice Department, Beirut Arab University
Email: lsoubra02@bau.edu.lb

ABSTRACT

Objective: The objectives of this study were to assess the prevalence of hypertension and the level of blood pressure (BP) control among a cohort of diabetic Lebanese patients on antihypertensive medications, as well as to identify factors associated with hypertension prevalence and uncontrolled BP.

Methods: This cross-sectional retrospective study was conducted in a tertiary health care clinic that is specialized in the management and follow-up of diabetic outpatients.

Results: Among the 700 type 2 diabetes mellitus patient files that were screened529 (75%) were found to have hypertension. Hypertension was more prevalent in women, patients aged ≥65-year-old, and those having a body mass index (BMI) ≥40 kg/m² (p-value<0.05). Among the hypertensive cohort, 465 T2DM were on antihypertensive medications and were included in the hypertension control analysis. Ninety-three patients (20%) attained BP control (SBP<140 and DBP<90 mmHg). Multivariate analyses revealed three factors that were significantly associated with uncontrolled BP control: Age being ≥65 y (adjusted OR = 1.96 (95% CI: 1.07–3.61, p-value<0.05), male gender (adjusted OR = 2.57, 95% CI: 1.41–4.66, p-value<0.05) and uncontrolled HDL (adjusted OR = 1.58, 95% CI: 1.33–2.01, p-value = 0.05).

Conclusion: Hypertension is prevalent among the study patients. However, attainment of BP control was poor among these patients. Therefore, there is a need for studies that determine reasons behind this low BP control rate in order to design interventions aiming at improving the standard of care for these patients.

Keywords: Diabetes Mellitus Type II, Hypertension risk factors, Hypertension prevalence, Blood pressure control, Lebanon

INTRODUCTION

Type 2 Diabetes Mellitus (T2DM) and hypertension (HT) are common chronic disorders that often coexist [1]. Large epidemiological studies showed that the coexistence of elevated Blood Pressure (BP) in patients with T2DM is associated with increased risk of mortality and morbidity because of cardiovascular complications [2-5]. Left ventricular hypertrophy and coronary artery disease were reported to be more common in diabetic hypertensive patients than in patients suffering from hypertension or diabetes alone [2]. Furthermore, it was reported that men with hypertension and T2DM have a 66% higher risk of suffering a stroke or heart attack than men who only have hypertension [5]. In these patients, a difference of 5 mmHg in either systolic blood pressure (SBP) or diastolic blood pressure (DBP) increases the risk of cardiovascular events or death by 20 to 30% [6].

Benefits of adequately controlling BP in diabetic patients have been documented by numerous studies [2, 7-9]. The action to control cardiovascular risk in diabetes (ACCORD) trial showed that patients with diabetes whose SBP ranged between 130 to 140 mm Hg were 46% less likely to die from any cause or suffer stroke or a nonfatal myocardial infarction (MI) [10]. Moreover, the hypertension optimal treatment (HOT) trial confirmed a 51% reduction in major cardiovascular events in the study group allocated to a target DBP of ≤ 80 mm Hg when compared with the group with a DBP of ≤ 90 mm Hg [11]. In the UK prospective study group, each 10 mm Hg decrease in SBP from baseline resulted in a 19% decrease in the risk of diabetes-related mortality, a 13% in all-cause mortality and a 13% decrease in MI [12]. BP control in patients with T2DM without overt albuminuria has also been shown to stabilize kidney function over a 5-year period [13].

Therefore, controlling BP in T2DM patients and maintaining this BP control throughout patient follow-up has been strongly recommended and in 2013, a target BP for T2DM patients was set at <140/90 mm Hg by the American diabetes association (ADA) [14].

Despite these recommendations which were based on the known benefits of lowering BP in preventing or slowing cardiovascular diseases in T2DM patients, studies consistently demonstrate that most diabetic patients do not achieve recommended levels of BP control and the majority have a BP>140/90 mm Hg [15, 16].

In Lebanon, the prevalence of diabetes is estimated to range from 8.5% to 15.8% among adults aged>25 y and according to the world health organisation (WHO) the number of people with diabetes is expected to significantly increase during the coming years [17, 18]. Moreover, two previous studies showed that among hypertensive Lebanese patients 23.9% and 27% were diabetics respectively [16-19] and that more than half of the hypertensive diabetics had uncontrolled BP [19]. There are scant data on the prevalence of hypertension in T2DM Lebanese patients, their status concerning BP control and factors affecting it. This information is highly needed to help manage cardiovascular risk factors and delay complications in these patients. Therefore, the present study was conducted with the aims of: (1) assessing the prevalence of high BP (i.e. SBP>140 and/or DBP ≥90 mm Hg) in a cohort of T2DM Lebanese patients, (2) determining the prevalence of controlled BP (SBP<140 mm Hg and DBP<90 mm Hg) among this cohort under current clinical practice and (3) identifying factors associated with uncontrolled BP (i.e. SBP>140 and/or DBP>90 mm Hg).

MATERIALS AND METHODS

Methods

The study was approved by the ethical committee of the Faculty of Pharmacy at Beirut Arab University as well as by the director of the clinic where the study was conducted. Ethical approval for a review board was not required since this is a descriptive retrospective study. All patient data were handled and processed in accordance to the recommendations of good clinical practice.

Design and setting

This cross-sectional retrospective study was conducted in a tertiary health care clinic that is specialized in the management and follow-
up of diabetic outpatients. The clinic which is located in Beirut city serves patients from across all regions of Lebanon (mainly from greater Beirut and Mount Lebanon regions that are home to 53.6% of the Lebanese population) and from a variety of socioeconomic backgrounds (mainly middle to high).

Data collection
Medical records of all patients who received care between January 2013 and December 2013 were consecutively screened to identify those with T2DM diagnosis as documented by the treating physician. Medical records of pregnant women patients, patients aged ≤ 18 y and those who did not authorize the use of their data were excluded from the study.

Data that were collected from the selected medical records included the followings: patient demographics (age and gender), social habits (smoking status and alcohol use), body mass index (BMI) and co-morbid conditions. A person was considered a non-smoker when the variable had responses of “no” or “ex-smoker”.

They also included DM related information which consisted of the presence of a family history of DM (i.e. presence of diabetes in any paternal or maternal relative), diabetes duration, presence of diabetes complications, fasting blood sugar (FBS) level, glycated Hemoglobin (HbA1c) level and antidiabetic medications. BP readings, prescribed antihypertensive (type and duration) and anti-platelet medications as well as patient lipid profile were also obtained.

All data were collected at the last clinic visit during the study period.

Lab data were categorized based on their control status prior analyzing the factors that were associated with uncontrolled BP. This was done using the following cut off points: fasting blood sugar (FBS) <70-130 mg/dl, glycated hemoglobin (HbA1c) value of <6.3 mmol/l (<7%), low density lipoprotein cholesterol (LDL-C) <1.8102 mmol/l (70 mg/dl) for T2DM patients with overt cardiovascular diseases or 2.586 mmol/l (100 mg/dl) for those without overt cardiovascular diseases, high density lipoprotein cholesterol (HDL-C) ≥1.034 mmol/l (40 mg/dl) in men, and ≥1.293 mmol/l (50 mg/dl) in women, serum triglycerides (TG) <1.693 mmol/l (150 mg/dl) and total cholesterol (TC) <5.172 mmol/l (200 mg/dl) [14].

Patients were initially grouped into two groups, those "with hypertension" and those "without hypertension". This was done using either a documented clinical diagnosis of hypertension in the medical record or the use of antihypertensive medications for lowering BP. The cut-off values used by the treating physician for hypertension diagnosis were a SBP >140 mm Hg and/or a DBP >90 mm Hg in three or more consecutive clinic visits, for those who were diagnosed during the year 2013 or a SBP >130 mm Hg and/or a DBP >80 mm Hg for those who were diagnosed prior that year. Patients in the "with hypertension" group were further divided into two subgroups: those with "controlled BP" (i.e. patients having SBP <140 mm Hg and/or DBP <90 mm Hg) and those with uncontrolled BP (i.e. patients having SBP ≥140 mm Hg or DBP ≥90 mm Hg). This was done using the means of two SBP and DBP readings obtained in the last clinic visit, taken 5 min apart by a trained nurse and comparing them to the 2013 ADA BP goals [14]. Patients who had no documented BP readings were excluded from this analysis.

Data were analyzed to identify firstly factors associated with hypertension prevalence and secondly factors associated with uncontrolled BP. The model with hypertension prevalence as outcome variable included the following covariates: age, gender, BMI, self-reported smoking status, alcohol use, diabetes mellitus duration and presence of dyslipidemia as co-morbid condition.

The model with controlled BP as outcome variable included all retrieved co-variates/predictor variables.

Statistical analysis
Data were entered and analyzed using the Statistical Package for Social Sciences (SPSS), version 21. Categorical variables were summarized by calculating the number and percent, whereas the continuous ones were summarized by calculating the mean and standard deviation. The chi-square test was used to assess the association between study outcome and the different categorical variables, whereas independent sample t-test was used for continuous ones. For categorical variables, odds ratios (OR) and 95% confidence interval (CI) were calculated.

Multivariate logistic regression analysis was carried out to identify independent factors that were associated with hypertension prevalence and those associated with uncontrolled BP. Adjusted OR and 95% CI were reported. A p-value of ≤ 0.05 was considered to be statistically significant.

RESULTS
One thousand fifty patients received care during the study period out of which 715 had T2DM. Fifteen patients were excluded from the study because either they were pregnant (10) or they refused authorization for use of their medical records [5]. Of the 700 T2 DM, 529 (75.5%) were hypertensives and 171 (24.5%) patients were not hypertensives. Moreover, of the hypertensive group, 64 hypertensive patients had no documentation of their BP readings and were therefore excluded from BP control analysis. The final sample consisted of 465 hypertensive patients (fig. 1).
total antihypertensive prescriptions, followed by beta-blockers (49.5%) and diuretics (40.2%) (table 4). 
Sixty-three percent of the patients were receiving antplatelet therapy either as monotherapy (58.1%) or as dual therapy (5.2%) (table 4). The most commonly prescribed antplatelet therapy was acetylsalicylic acid (46.7%) (table 4). Multivariate analysis showed that hypertension was more prevalent in female T2DM patients than male patients (OR=1.43, 95% CI: 1.15–1.72, p-value<0.05), in patients aged ≥ 65 y-old, (OR = 3.23, 95% CI: 1.62–14.74, p-value<0.05), obese (OR= 1.32, 95% CI: 1.1–2.30, p-value<0.05) and in those having dyslipidemia (OR = 1.62, 95% CI: 1.3–1.89, p-value<0.05). Hypertension prevalence was not found to be significantly associated with the duration of diabetes mellitus (p-value=0.05).

Table 1: Association between hypertension prevalence and demographic, social habits and health status among the cohort of type 2 diabetes mellitus Lebanese patients

| Variables            | Total N (%) | No hypertension N (%) | Hypertension N (%) | OR (95% CI) | P-value | Adjusted OR (95%) | P-value |
|----------------------|-------------|-----------------------|--------------------|-------------|---------|--------------------|---------|
| **Age (years)**      |             |                       |                    |             |         |                    |         |
| Mean (sd) ≥ 65       | 585 (12.3)  | 510 (11.6)             | 60.9 (11.6)        | 6.23 (3.62–10.72) | 0.001  | 3.23 (1.62–14.74)  | 0.03    |
| Male Gender          |             |                       |                    |             |         |                    |         |
| Mean (sd)            | 405 (57.9%) | 113 (46.1%)            | 292 (55.2%)        | 1.58 (1.10–2.27) | 0.01   | 1.43 (1.15–3.22)   | 0.002   |
| Male                  |             |                       |                    |             |         |                    |         |
| Mean (sd) BMI* Normal (18.5–24.9) |               |                       |                    |             |         |                    |         |
| Mean (sd) Overweight (25–29.9) |               |                       |                    |             |         |                    |         |
| Mean (sd) Obese (≥ 30) |              |                       |                    |             |         |                    |         |
| Current smoker       |             |                       |                    |             |         |                    |         |
| Current alcohol user |             |                       |                    |             |         |                    |         |
| Duration of diabetes |             |                       |                    |             |         |                    |         |
| Reference            |             |                       |                    |             | <0.0001 |                  |         |
| Female                |             |                       |                    |             |         |                    |         |
| Male                  |             |                       |                    |             |         |                    |         |
| Dyslipidemia          |             |                       |                    |             |         |                    |         |
| Reference             |             |                       |                    |             |         |                    |         |

*BMI: body mass index

**Blood pressure control subgroup analysis**

Table 2 summarizes the demographic and clinical characteristics of hypertensive patients included in the study, as stratified by BP control status. Nighty-three percent (20%) attained BP control, whereas the remaining 372 patients did not attain BP control (80%). The uncontrolled BP group was found to be significantly older (mean = 62.1±11.0 y-old) as compared to the controlled BP one (mean = 57.2±11.1 y-old, p-value<0.001). Similarly, the uncontrolled BP patients were more likely to be males (OR = 5.03, 95% CI: 2.86–8.86; p-value<0.001). There was no statistically significant difference in the BMI between the uncontrolled BP group and the controlled one. Although smokers and alcohol consumers were less likely to be uncontrolled, the association was not statistically significant (p-value>0.05). Similarly, diabetes-related information was not statistically different between the controlled and uncontrolled BP groups and these included the family history of DM, duration of DM and comorbid conditions. Patients diagnosed with isolated systolic hypertension (SBP) were more prone to be uncontrolled (OR = 2.85, 95% CI: 1.26–6.42, p-value<0.05).

Lab results of the patients included in this study, as stratified by the BP control status are presented in table 5. The only variable that was found to be statistically associated with uncontrolled BP is HbA1C, where the uncontrolled BP group was more likely to be uncontrolled according to their HbA1C value (OR=2.85, 95% CI: 1.71–4.71, p-value<0.05). Although both FBS and HbA1C were not statistically different between the two groups, it was found that the uncontrolled BP group were more likely to have uncontrolled FBS (OR = 1.55, 95% CI: 0.95–2.53, p-value<0.05) and uncontrolled A1C (OR = 1.53, 95% CI: 0.96–2.46, p-value<0.05). Similarly, the uncontrolled BP group were less likely to be controlled according to their lipid profile. However, this association was not significant: OR for patients having LDL ≥100 mg/dl was 1.34 (95% CI: 0.69–2.58, p-value>0.05), OR for patients having TG ≥150 mg/dl was 1.09 (95% CI: 0.69–1.72, p-value>0.05) and OR for patients having TG≥200 mg/dl was 1.19 (95% CI: 0.70–2.02, p-value>0.05).

Table 4 summarizes details of the medications used by the study sample stratified according to BP control. There was no statistical difference between the groups concerning the type of antihypertensive, antplatelet and lipid-lowering medications use. Although the number of antihypertensive medications used was not statistically different between the two groups, uncontrolled BP group were more prone to use a lower number of antihypertensive medications: OR = 0.99 (95% CI: 0.59–1.76, p-value<0.05). For those using two antihypertensive medications versus OR = 0.65 (95% CI: 0.4–1.06, p-value<0.05) for those using more than two antihypertensive medications. Something worth highlighting is the finding that patients using incretin mimetics (glucagon-like peptide 1 (GLP-1) analogs) were less likely to have uncontrolled BP and this association was statistically significant (OR= 0.30, 95% CI: 0.18–0.49; p-value<0.005).

Finally, after adjusting for all covariates, multivariate analysis showed that only three factors were significantly associated with uncontrolled BP: Age being ≥65 y (OR = 1.96 (95% CI: 1.07–3.61, p-value = 0.03); male gender (OR = 2.57, 95% CI: 1.41–4.66, p-value = 0.002); and uncontrolled HDL (OR = 1.58, 95% CI: 1.33–2.01, p-value = 0.03).
Table 2: Study sample demographic characteristics stratified according to BP control

| Variables                              | Total N (%) | BP controlled N (%) | BP uncontrolled N (%) | OR (95% CI) | P-value | Adjusted OR (95%) | P-value |
|----------------------------------------|-------------|---------------------|-----------------------|-------------|---------|--------------------|---------|
|                                        | N = 465     | N = 93              | N = 372               |             |         |                    |         |
| Age (years)                            |             |                     |                       |             |         |                    |         |
| ≥ 65                                   | 186 (40.0%) | 16 (17.2%)          | 170 (45.7%)           | 4.08 (2.28-7.20) | 0.001   | 1.96 (1.07-3.61)  | 0.03    |
| Gender                                 |             |                     |                       |             |         |                    |         |
| Male                                   | 214 (54.0%) | 17 (18.2%)          | 197 (52.9%)           | 5.03 (2.86-8.86) | 0.001   | 2.57 (1.41-4.66)  | 0.002   |
| BMI                                    |             |                     |                       |             |         |                    |         |
| Mean (sd)                              |             |                     |                       |             |         |                    |         |
| Normal (18.5-24.9)                     | 310 (5.5)   | 30.6 (5.2)          | 31.0 (5.7)            | Reference   | 0.59    |                    |         |
| Overweight (25-29.9)                   | 46 (11.0%)  | 16 (17.2%)          | 30 (8%)               | 1.9 (0.93-3.86) | 0.007   | 1.82 (0.73-4.54)  | 0.20    |
| Obese (≥ 30)                           | 209 (49.9%) | 50 (38.7%)          | 159 (42.7%)           | 1.7 (0.85-3.30) | 0.13    | 1.26 (0.53-2.95)  | 0.60    |
| Current smoker                         |             |                     |                       |             |         |                    |         |
|                                       | 263 (56.6%) | 58 (62.3%)          | 205 (55.1%)           | 0.74 (0.46-1.18) | 0.21    | 0.88 (0.51-1.50)  | 0.63    |
| Current alcohol user                   |             |                     |                       |             |         |                    |         |
|                                       | 87 (18.7%)  | 20 (21.5%)          | 67 (18.0%)            | 0.67 (0.39-1.22) | 0.22    | 0.72 (0.38-1.35)  | 0.30    |
| Isolated systolic hypertension at diagnosis |               |                     |                       |             |         |                    |         |
|                                       | 77 (66.9%)  | 7 (11.8%)           | 70 (17.7%)            | 2.85 (1.26-6.42) | <0.01   | 1.96 (0.96-6.42)  | 0.09    |
| Family history of diabetes             |             |                     |                       |             |         |                    |         |
|                                       | 308 (66.2%) | 58 (62.3%)          | 250 (67.2%)           | 1.24 (0.77-1.98) | 0.38    | 0.95 (0.54-1.67)  | 0.86    |
| Duration of diabetes                  |             |                     |                       |             |         |                    |         |
| Mean (sd)                              |             |                     |                       |             |         |                    |         |
| <1 y                                   | 8.6 (8.1)   | 7.0 (8.0)           | 8.9 (8.0)             | Reference   | 0.07    | -                  | 0.07    |
| 1-5y                                   | 55 (12.1%)  | 15 (16.1%)          | 40 (10.7%)            | 1.20 (0.59-2.42) | 0.61    | 0.94 (0.41-2.16)  | 0.89    |
| 6-10 y                                 | 112 (24.6%) | 22 (23.6%)          | 90 (24.0%)            | 1.53 (0.72-3.26) | 0.26    | 1.02 (0.43-2.45)  | 0.96    |
| >10 y                                  | 138 (30.3%) | 28 (30.1%)          | 110 (24.2%)           | 1.47 (0.71-3.04) | 0.29    | 2.26 (0.88-5.80)  | 0.09    |
| Diabetic complications                 |             |                     |                       |             |         |                    |         |
| Macrovacular                           | 146 (31.4%) | 32 (34.4%)          | 114 (30.6%)           | 0.84 (0.52-1.38) | 0.58    | 0.86 (0.49-1.49)  | 0.58    |
| Neuropathy                             | 90 (19.4%)  | 10 (17.9%)          | 80 (21.5%)            | 1.35 (0.66-2.76) | 0.42    | 1.13 (0.66-2.46)  | 0.42    |
| Retinopathy                            | 42 (9.0%)   | 7 (17.9%)           | 35 (9.4%)             | 1.28 (0.55-2.97) | 0.57    | 1.20 (0.45-3.18)  | 0.71    |
| Proteinuria                            | 160 (34.4%) | 30 (32.2%)          | 130 (35 %)            | 1.13 (0.70-1.83) | 0.63    | 1.40 (0.78-2.51)  | 0.26    |
| Number of complications                |             |                     |                       |             |         |                    |         |
| 0                                      | 168 (36.1%) | 37 (39.7%)          | 131 (35.2%)           | 1.28 (0.76-2.17) | 0.35    | 1.32 (0.73-2.43)  | 0.35    |
| 1                                      | 183 (39.4%) | 33 (35.4%)          | 150 (40.3%)           | 1.32 (0.69-2.54) | 0.4     | 1.55 (0.71-3.37)  | 0.27    |
| 2                                      | 91 (19.6%)  | 16 (17.2%)          | 75 (20.2%)            | 1.32 (0.69-2.54) | 0.98    | 0.91 (0.29-2.89)  | 0.87    |
| >2                                     | 23 (5.0%)   | 5 (5.3%)            | 18 (4.8%)             | 1.02 (0.35-2.92) | 0.01    |                    |         |

*BMI: body mass index

Table 3: Study sample lab data stratified according to BP control

| Variables                     | Total N (%) | BP controlled N (%) | BP uncontrolled N (%) | OR (95% CI) | P-value | Adjusted OR (95%) | P-value |
|------------------------------|-------------|---------------------|-----------------------|-------------|---------|--------------------|---------|
|                              | N = 465     | N = 93              | N = 372               |             |         |                    |         |
| FBS (mmol/l)                 | Mean (sd)   |                     |                       |             |         |                    |         |
| ≥ 7.32 mmol/l                | 9.86 (4.3)  | 9.44 (4.75)         | 9.93 (4.2)           | 1.55 (0.95-2.53) | 0.45    | 1.91 (0.97-3.93)  | 0.06    |
| HbA1C (mmol/l)               | Mean (sd)   |                     |                       |             |         |                    |         |
| ≥ 6.3 mmol/l                 | 9.44 (4.75) | 9.39 (5.48)         | 110 (5.65%)          | Reference   | 0.59    |                    |         |
| LDL-C (mmol/l)               | Mean (sd)   |                     |                       |             |         |                    |         |
| <1.8102 mmol/l               | 56 (14.9%)  | 17 (18.3%)          | 39 (10.5%)           | Reference   | 0.31    |                    | 0.31    |
| 1.8102-2.56014 mmol/l        | 130 (34.5%) | 27 (29%)            | 103 (27.7%)          | 0.94 (0.57-1.55) | 0.07    | 1.43 (0.80-2.58)  | 0.23    |
| ≥ 2.5866 mmol/l              | 191 (50.7%) | 47 (50.5%)          | 144 (38.7%)          | 1.34 (0.69-2.58) | 0.39    | 0.87 (0.36-2.11)  | 0.76    |
| HDL-C                        | Mean (sd)   |                     |                       |             |         |                    |         |
|                             | 1.132 (0.310) | 1.029 (0.284)     | 1.148 (0.312)        |             | 0.01    |                    |         |
Hypertension is a major cardiovascular risk factor for patients with T2DM especially if target BP is not reached. In this study, we assessed the prevalence of hypertension and BP control status among a cohort of T2DM Lebanese patients as well as we identified the factors associated with being BP uncontrolled. This study showed that hypertension is prevalent in 75% of T2DM patients. This result is similar to those reported in the literature where prevalence rates ranged from 60% to 80% depending on the sample size and patient’s race [1, 20, 21].

Moreover, this study highlighted that age older than 65 y, obesity, female gender as well as presence of dyslipidemia are factors that were associated with hypertension prevalence. These findings are in alignment with those reported in the literature where age, female gender, obesity and extensive atherosclerosis were reported as risk factors for hypertension development in T2DM patients [22].

The low prevalence of controlled BP among hypertensive T2DM patients found in this study (20%) was comparable to findings in several studies reported in the literature. For example, in a study conducted between 2005 and 2006 in 26 countries, the overall BP control rate was 33.6% in men and 30.6% in women and was lower

Table 4: Drug treatment of the study sample stratified according to BP control

| Variables                          | Total N (%) | BP controlled N (%) | BP uncontrolled N (%) | OR (95% CI) | P-value | Adjusted OR (95%) | P-value |
|------------------------------------|-------------|---------------------|-----------------------|-------------|---------|------------------|---------|
| N = 465                            | N = 93      | N = 372             |                       |             |         |                  |         |
| Anti-hypertensive agents           |             |                     |                       |             |         |                  |         |
| ACEIs                              | 222 (24.6%) | 42 (45%)            | 180 (84.4%)           | 1.14 (0.72–1.8) | 0.58    | 0.85 (0.48–1.51) | 0.58    |
| ARBs                               | 234 (25.8%) | 46 (49.5%)          | 188 (80.5%)           | 1.16 (0.74–1.8) | 0.53    | 1.58 (0.92–2.69) | 0.10    |
| BBs                                | 230 (25.8%) | 48 (51.6%)          | 182 (84.9%)           | 0.90 (0.57–1.41) | 0.64    | 1.31 (0.77–2.22) | 0.33    |
| Diuretics**                        | 187 (20.6%) | 33 (35.5%)          | 154 (81.4%)           | 1.07 (0.66–1.74) | 0.76    | 1.23 (0.71–2.13) | 0.45    |
| CCBs                               | 125 (13.5%) | 20 (21.5%)          | 105 (82.8%)           | 1.44 (0.83–2.47) | 0.19    | 1.24 (0.67–2.29) | 0.50    |
| Alpha-2 agonist                    | 9 (1.9%)    | 1 (1%)              | 8 (21%)               | 2.02 (0.25–6.37) | 0.50    | 1.28 (0.16–10.43) | 0.82    |
| Number of anti-hypertensive medications |             |                     |                       |             |         |                  |         |
| 1                                  | 172 (37.0%) | 37 (39.8%)          | 137 (61.6%)           | Reference   |         |                  |         |
| 2                                  | 166 (35.7%) | 36 (38.7%)          | 130 (78.3%)           | 0.99 (0.59–1.66) | 0.97    | 1.80 (0.56–2.89) | 0.90    |
| >2                                 | 127 (27.3%) | 32 (34.4%)          | 95 (75.5%)            | 0.65 (0.4–1.06) | 0.09    | 0.74 (0.43–1.26) | 0.26    |
| Statins                            | 267 (57.4%) | 55 (59.1%)          | 212 (57%)             | 0.92 (0.58–1.45) | 0.71    | 1.14 (0.67–1.93) | 0.63    |
| Anti-platelet medications          |             |                     |                       |             |         |                  |         |
| Aspirin                            | 217 (46.7%) | 39 (41.9%)          | 178 (87.4%)           | 1.27 (0.80–2.01) | 0.82    | 1.07 (0.63–1.81) | 0.82    |
| Clopidogrel                        | 53 (11.4%)  | 16 (17.2%)          | 37 (9.9%)             | 0.59 (0.31–1.13) | 0.11    | 0.56 (0.27–1.16) | 0.12    |
| Aspirin + clopidogrel              | 24 (5.2%)   | 4 (3.1%)            | 20 (5.5%)             | 1.28 (0.42–3.19) | 0.68    | 1.80 (0.41–7.84) | 0.43    |
| Anti-diabetic agents                |             |                     |                       |             |         |                  |         |
| Metformin                          | 348 (74.8%) | 68 (73.1%)          | 280 (75.2%)           | 1.12 (0.67–1.87) | 0.67    | 0.99 (0.54–1.82) | 0.97    |
| Sulphonylureas                     | 218 (46.9%) | 39 (42%)            | 179 (84.8%)           | 1.28 (0.81–2.03) | 0.29    | 1.08 (0.63–1.83) | 0.79    |
| Incretin mimetics***               | 98 (21.1%)  | 17 (18.2%)          | 81 (21.7%)            | 0.30 (0.18–0.49) | <0.05   | 0.70 (0.38–1.28) | 0.25    |
| Thiazolidinedione                  | 33 (7.1%)   | 4 (4.3%)            | 29 (7.8%)             | 1.08 (0.64–5.49) | 0.24    | 1.17 (0.14–3.45) | 0.78    |
| Insulin alone                      | 96 (20.8%)  | 20 (21.5%)          | 76 (20.4%)            | 0.94 (0.54–1.63) | 0.82    | 1.47 (0.62–3.49) | 0.29    |
| Insulin + others                   | 65 (14.0%)  | 17 (18.3%)          | 48 (12.9%)            | 1.51 (0.82–2.77) | 0.18    | 1.38 (0.60–3.17) | 0.45    |

| FSB: fasting blood sugar; HbA1C: glycated hemoglobin; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: serum triglycerides; TC: total cholesterol; *Uncontrolled for men was at<1.034 mmol/l, whereas for women was at<1.293 mmol/l

DISCUSSION

Hypertension is a major cardiovascular risk factor for patients with T2DM especially if target BP is not reached. In this study, we assessed the prevalence of hypertension and BP control status among a cohort of T2DM Lebanese patients as well as we identified the factors associated with being BP uncontrolled.

This study showed that hypertension is prevalent in 75% of T2DM patients. This result is similar to those reported in the literature where prevalence rates ranged from 60% to 80% depending on the sample size and patient's race [1, 20, 21].
in diabetic as compared to non-diabetic patients [23]. Another study
carried out in the United States by Grant et al. also reported similar
prevalence of BP control (33%) [24]. The low BP control rate among
T2DM patients was reported to be related to the poor adherence to
antihypertensive medications that has been reported to be as low as
43% to 5-27. Other reasons that might be implicated in poor BP
care includes failure to adopt a healthy lifestyle (diet and exercise),
derestimulation of the potential complications of hypertension, absence of effective health education programs and
low level of education and/or low socioeconomic levels [26-28].
Clinical inertia, which is the failure of health care providers to
initiate or intensify therapy when indicated, was also reported as a
key player that prevent BP goal attainment [29, 30].

On the other hand, other studies have reported a better prevalence of
controlled BP as compared to our findings. For instance, two
studies showed that around half of hypertensive diabetic patients
are meeting target BP values [31, 32]. Barquilla et al. and
Abougalambou et al. reported controlled BP rates in T2DM patients
of 56.4%, and 47.2% respectively [33, 34].

As for the factors associated with uncontrolled BP in our study, it was
found that age ≥65 y was associated with uncontrolled BP. Similar to
our study, older age was significantly associated with uncontrolled
BP as reported by Abougalambou et al. and by Duggirala et al. [34, 35].

Another factor found to significantly predict uncontrolled BP in our
study was male gender (OR = 2.37, 95% CI: 1.41-4.66, p-value =
0.001). Similar results were found in a study carried by Cummings et al. [36]. On the contrary Duggirala et al. reported that female gender
was a significant predictor of uncontrolled BP in their study [37]. Moreover, other studies reported that gender was not
associated with uncontrolled BP [33, 34, 38, 39]. This can be
explained by the fact that the mechanisms by which blood pressure
increases in men and women with aging may be different after
menopause [40].

On the other hand, we found that uncontrolled HDL in our study was
associated with higher odds of having uncontrolled BP. This is in
alignment with the theory that HDL is cardioprotective leading to
a better control of BP [41].

Predictably, we did not find any statistical significance regarding
association between uncontrolled blood pressure and elevated total
cholesterol, elevated BMI as well as the number of antihypertensive
medications. These findings were different from those reported by
other studies. For instance, a study carried out by Barquilla et al. in
2014 reported a strong association between elevated total cholesterol and uncontrolled BP [33]. In a study carried out by
Mubarak et al. in Jordan, it was reported that uncontrolled BP was
positively associated with BMI (P=0.001) [38]. Basile et al. in 2013
reported that the administration of at least one antihypertensive
medication is associated with better blood pressure control [42].
Finally, one important finding that worth being highlighted is that
the use of incretin mimetics (glucagon-like peptide-1 (GLP-1)
analogs) was associated with a higher prevalence of blood pressure
control. However, this study failed to identify their use as an
independent predictor of BP control. This may be due to the small
sample size of patients receiving these medications or the presence
of confounding variables that distorted the association between the
use of these drugs and BP control. The positive effects of these drugs
on lowering BP is reported in the literature [43, 44]. Therefore, this
result should be investigated by future studies.

Strengths and limitations
The results of this study should be evaluated in the light of its
strengths and limitations. Being among few addressing this important
topic in the Middle East is its main strength. One of the limitations
of the study is its observational nature as well as the lack of follow-up of
patients over time. A single visit was taken into consideration when
assessing control of BP. This might have led to some bias in
the estimation of the BP control level, since they were recorded at one
point in time. Moreover, the ADA (less stringent) BP goals were used.
This might have had also overestimated the percentage of patients at
BP goals. In addition, this study did not look at factors that might have
contributed to the low rates of controlled BP such as medication
adherence, appropriateness of prescribed antihypertensive
medications (type and dosage regimen) as well as clinical inertia.
Therefore, further studies on this subject are required.

CONCLUSION
This study showed that more than three-fourth of hypertensive T2DM patients have their BP uncontrolled in Lebanon.

According to this study attention should be given to patients who are ≥65-year-old, male patients and those having uncontrolled HDL levels. They should be selected for intervention programs that might improve their BP control. These intervention programs might include, but are not limited to, assessment of BP goals achievement and intensifying/ modifying antihypertensive medications accordingly at each clinic visit as well as educating patients on their disease status and related behavioral changes. These interventions could lead to better BP control rates, decreasing therefore the risk for macrovascular complications and minimizing the health care expenditures in a country where the health resources are limited.

Moreover, the finding of a possible positive association between the use of incretin mimetics and BP control highlights the promising role of these drugs in the management of T2DM patients and opens the door for the need of further studies in this regard.

Funding
There was no funding for this study.

CONFLICT OF INTERESTS
All authors declare that they have no conflict of interest.

REFERENCES
1. Colosia AD, Palenica R, Khan S. Prevalence of hypertension and
obesity in patients with type 2 diabetes mellitus in observational studies: a systematic literature review. Diabetes
Metab Syndr Obes: Targets Ther 2013;6:327-38.
2. Grossman E, Messerli F. Hypertension and diabetes. Adv
Cardiol 2008;45:82-106.
3. Campbell N, Gilbert R, Leiter L, Larochelle P, Tobe S, Chockalingam A, et al. Hypertension in people with type 2
diabetes: Update on pharmacologic management. Canadian
Family Physician 2011;57:997-1002, e347-53.
4. Song S, Hardt C. Type 2 diabetes mellitus: a high-risk
case for cardiovascular disease irrespective of the
different degrees of obesity. Q J Med 2008;101:875-9.
5. Estacio RO, Jeffers BW, Gifford N, Schirer RW. Effect of
drug pressure control on diabetic microvascular complications in
patients with hypertension and type 2 diabetes. Diabetes Care
2003;26 Suppl 2:54-64.
6. Cushman W, Evans G, Byington R, Goff D, Grimm R, Cutler J.
Effects of intensive blood-pressure control in type 2
mellitus. N Engl J Med 2010;362:1575-85.
7. Mancia G, Laurent S, Agabiti-Rossi E, Ambrosioni E, Burniere
M, Guelffidd M, et al. Reappraisal of European guidelines on
hypertension management: a European society of hypertension
task force document. J Hypertens 2009;27:2121-58.
8. Lopez-Jaramillo P, Lopez-Lopez, J, Lopez-Carez, R, Rodriguez-
Alvarez M. The goal of blood pressure in the hypertensive
patient with diabetes is defined: now the challenge is go from
recommendations to practice. Diabetol Metab Syndr 2014;6:311.
9. Holman R, Paul S, Bethel M, Neil H, Matthews D. Long-term
follow-up after tight control of blood pressure in type 2
diabetes. N Engl J Med 2008;359:1565-76.
10. The Action to Control Cardiovascular Risk in Diabetes Study
Group. Effects of intensive blood pressure control in type 2
diabetes mellitus. N Engl J Med 2008;359:2545-59.
11. Hanson L, Zanchetti A, Carruthers S, Dahlof B, Elmfeldt D, Julius
S, et al. Effects of intensive blood pressure lowering and
low-dose aspirin in patients with hypertension: principal results of
the hypertension optimal treatment (HOT) randomized trial.
Lancet 1998;351:1755-62.
12. UK Prospective diabetes study group. Tight blood pressure
control and risk of macrovascular and microvascular complications
in type 2 diabetes: UKPADS 38. Br Med J 1998;317:703-13.
13. National Collaborating Centre for Chronic Conditions (UK). Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update). London: Royal College of Physicians (UK); 2008. Available from: http://www.ncbi.nlm.nih.gov/books/NBK53885. [Last accessed on 06 May 2016]

14. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2013;36 Suppl 1:11–66.

15. Bangalore S, Kumar S, Lobach I, Messerli F. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and Bayesian random-effects meta-analyses of randomized trials. Circulation 2011;123:2799–810.

16. Cha boud J, Mrad J, Semaan A, Asmar R. Prevalence of diabetes mellitus among patients with essential arterial hypertension. J Med Liban 2015;63:74–80.

17. Costan tian C, Benett C, Hawilla N, Assaad C, Sibai A. Prevalence, correlates and management of type 2 diabetes mellitus in Lebanon: Findings from a national population-based study. Diabetes Res Clin Pract 2014;105:408–15.

18. World Health Organisation. Prevalence of diabetes in the World Health Organisation. Prevalence of diabetes in the Eastern Mediterranean Region. Available from: http://www.who.int/diabetes/facts/world_figures/index2.html. [Last accessed on 06 May 2016]

19. Tohme RA, Juris AS, Esteban A. The prevalence of hypertension and its association with other cardiovascular disease risk factors in a representative sample of the Lebanese population. J Hum Hypertens 2005;19:861–8.

20. Khan NA, Venkatachalal VV, Alavudeen SS, Dhanapal CK, Ansari SMA. Therapeutic management of hypertension and hyperlipidemia in type-2 diabetes mellitus patients in southwestern region of Saudi Arabia: a pharmacist perspective. Asian J Pharm Clin Res 2014;7:241–5.

21. Andayan TMI, Mohamed Ibrahim MI, Asdie AH. Assessing the impact of complications on the direct medical costs of type 2 diabetes mellitus outpatients. Int J Chem Pharm Res 2010;2:32–5.

22. Simonson D. Etiology and prevalence of hypertension in diabetic patients. Diabetes Care 1988;11:821–5.

23. Bell D. Treatment of diabetic hypertension. Diabetes Obes Metab 2009;11:433–44.

24. Grant RW, Buse JB, Meigs JB. Quality of diabetes care in U. S. academic medical centers: low rates of medical regimen change. Diabetes Care 2005;28:337–44.

25. Erdine S. Compliance with the treatment of hypertension: the potential of combination therapy. J Clin Hypertens 2010;12:49–66.

26. Fung V, Huang J, Brand R, Newhouse J, Hsu J. Hypertension treatment in a medicare population: adherence and systolic blood pressure control. Clin Ther 2007;29:972–84.

27. Muszbek N, Brixner D, Benedict A, Eskenslakian A, Khan Z. The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review. Int J Clin Pract 2006;60:238–51.

28. Cheung B, Li C. Diabetes and hypertension: is there a common metabolic pathway? Curr Atheroscler Rep 2012;14:160–6.

29. Basile J. Clinical inertia and blood pressure goal attainment. J Clin Hypertens 2009;11(12, Suppl 1):5–12.

30. O’Connor P, Sper-Hil len J, Johnson P, Rush W, Blitz G. Clinical inertia and outpatient medical errors. In: Henrikson K, Battles JB, Marks ES, editors. Advances in Patient Safety: From Research to Implementation (Volume 2: Concepts and Methodology). Rockville (MD): Agency for Healthcare Research and Quality (US); 2005. p. 293–308.

31. Cummings D, Doherty J, Howard G, Howard V, Safford M, Prince V, et al. Blood pressure control in diabetes: temporal progress yet persistent racial disparities: national results from the R Easons for geographic and racial differences in stroke (REGARDS) study. Diabetes Care 2010;33:790–803.

32. Egan B, Zhao Y, Axon R. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA 2010;303:2043–50.

33. Barqalla G, Isterri J, Prieto M, Alonso-Moreno F, Matarrin G, Nafria G, et al. Blood pressure control in a population of hypertensive diabetic patients treated in primary care: PRESCAP-diabetes Study 2010. SEMERGEN-Med Familia 2015;41:13–23.

34. Abuogambou S, Abuogambou A. A study evaluating prevalence of hypertension and risk factors affecting on blood pressure control among type 2 diabetes patients attending teaching hospital in Malaysia. Diabetol Metab Syndr 2013;5:85–6.

35. Duggirala M, Cuddihy R, Cuddihy M, Naessens J, Cha S, Mandrekar J, et al. Predictors of blood pressure control in patients with diabetes and hypertension seen in primary care clinics. Am J Hypertens 2005;18:833–8.

36. Cummings D, Letter A, Howard G, Howard V, Safford M, Prince V, et al. Generic medications and blood pressure control in diabetic hypertensive subjects: results from the Reasons for geographic and racial differences in stroke (REGARDS) study. Diabetes Care 2013;36:591–7.

37. Lopez-Ruiz A, Sartori-Valinotti J, Yanes L, Iliescu R, Rebekhoff L. Sex differences in control of blood pressure: role of oxidative stress in hypertension in females. Am J Physiol Heart Circ Physiol 2008;295:466–74.

38. Xiao E, Gao P, Zhang J, Wu HM. Influence of low high-density lipoprotein cholesterol on arterial stiffening and left ventricular diastolic dysfunction in essential hypertension. J Clin Hypertens 2011;13:710–5.

39. Basile J, Bloch M. Analysis of recent papers in hypertension: nighttime administration of at least one antihypertensive medication is associated with better blood pressure control and cardiovascular outcomes in patients with type 2 diabetes or chronic kidney disease. J Clin Hypertens 2013;15:52–4.

40. Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, et al. Blood-pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab 2013;15:737–49.

How to cite this article

- Lama Soubra, Hanan Nurredin, Amal Galal Omar, Mounezer Saleh. Factors associated with hypertension prevalence and control among lebanese type 2 diabetic patients. Int J Pharm Pharm Sci 2016;8(10):153-159.